Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review

Expert Rev Anti Infect Ther. 2013 Jan;11(1):69-78. doi: 10.1586/eri.12.149.


The authors sought to evaluate the impact of ertapenem use on the resistance of Gram-negative bacteria (in general and in specific species) to group 2 carbapenems. PubMed and Scopus databases were systematically searched. Eight studies were included; all reported on Pseudomonas aeruginosa and four reported on Enterobacteriaceae. Five studies did not show any difference in group 2 carbapenem resistance for P. aeruginosa, while three reported a significant decline after ertapenem introduction. Three studies did not show any difference in group 2 carbapenem resistance between the compared periods for Enterobacteriaceae and one study did not present a statistical analysis. In conclusion, the currently available data suggest that ertapenem use does not affect the resistance of Gram-negative bacteria to group 2 carbapenems.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use
  • Ertapenem
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacteria / physiology
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / physiopathology
  • Humans
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / physiology
  • beta-Lactam Resistance / drug effects*
  • beta-Lactam Resistance / physiology
  • beta-Lactams / pharmacology
  • beta-Lactams / therapeutic use*


  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactams
  • Ertapenem